EIB Loans €400M to Fresenius for Affordable Healthcare Innovations
The European Investment Bank (EIB) has shown its commitment to affordable healthcare by loaning €400 million to Fresenius, a leading global healthcare group. The loan, facilitated by Nicola Beer, Vice President of the EIB, will support Fresenius' innovative research and development in lifesaving medicines and technologies.
Fresenius will utilise the funds to expand its manufacturing of medical products and biosimilars in Europe. This includes investments in its portfolio of biosimilars, generic drugs, infusion therapies, clinical nutrition products, and related administration devices. The company aims to increase the availability of these innovative, affordable solutions for patients across Europe.
Generic drugs, which account for around 70% of prescriptions in Europe, currently represent only just under 20% of pharmaceutical costs. Fresenius' efforts, backed by the EIB, aim to bridge this gap and reduce the financial burden on European healthcare systems.
The EIB's loan to Fresenius is part of its broader strategy to strengthen the resilience of pharmaceutical production in the EU. It aligns with Fresenius' FutureFresenius agenda and demonstrates the EIB's dedication to high-quality, affordable healthcare. Sara Hennicken, CFO of Fresenius, welcomed the loan as a recognition of the company's contribution to a healthy European future.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
